The IDH‐mutant gliomas are particularly dependent on the de novo pyrimidine biosynthesis, since inhibitors targeting enzymes of this metabolism including DHODH, preferentially kill IDH1‐mutant glioma cells and patient‐derived IDH‐mutant GSC compared to IDH‐wild type cells. This evidence concerns the gene IDH1 and central nervous system cancer.